Targeting Eukaryotic Translation Initiation Factor 4E (eIF4E) in Cancer
Open Access
- 13 October 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (20), 4914-4920
- https://doi.org/10.1158/1078-0432.ccr-10-0433
Abstract
Recent advances in understanding the role of eukaryotic translation initiator factor 4E (eIF4E) in tumorigenesis and cancer progression have generated significant interest in therapeutic agents that indirectly or directly target aberrant activation of eIF4E in cancer. Here, we address the general function of eIF4E in translation initiation and cancer, present evidence supporting its role in cancer initiation and progression, and highlight emerging therapeutics that efficiently target hyperactivated eIF4E. In doing so, we also highlight the major differences between these therapeutics that may influence their mechanism of action. Clin Cancer Res; 16(20); 4914–20. ©2010 AACR.Keywords
This publication has 46 references indexed in Scilit:
- Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4ECancer Cell, 2010
- Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)Biochemical Journal, 2009
- Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activityBritish Journal of Cancer, 2009
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1Published by Elsevier BV ,2009
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2PLoS Biology, 2009
- Palomid 529, a Novel Small-Molecule Drug, Is a TORC1/TORC2 Inhibitor That Reduces Tumor Growth, Tumor Angiogenesis, and Vascular PermeabilityCancer Research, 2008
- Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translationProceedings of the National Academy of Sciences of the United States of America, 2008
- Inhibition of Polysome Assembly Enhances Imatinib Activity against Chronic Myelogenous Leukemia and Overcomes Imatinib ResistanceMolecular and Cellular Biology, 2008
- Dissecting eIF4E action in tumorigenesisGenes & Development, 2007
- Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicityJCI Insight, 2007